AAPS PHARMSCITECH is a prestigious peer-reviewed journal published by Springer, focusing on the dynamic field of pharmaceutical sciences and technology. With an ISSN of 1530-9932, it provides a vital platform for disseminating cutting-edge research that spans key areas including drug discovery, pharmacology, toxicology, and ecological impacts of pharmaceuticals. The journal is recognized for its rigorous scientific contributions, currently holding a commendable Q2 quartile ranking across several relevant categories, including Agronomy and Crop Science, Aquatic Science, and Medicine in 2023. Notably, it ranks 43rd out of 183 in the Scopus Pharmacology, Toxicology, and Pharmaceutics category, placing it in the 76th percentile of its field. Aiming to foster innovation and collaboration among researchers, professionals, and students, AAPS PHARMSCITECH is committed to advancing scientific knowledge and addressing contemporary challenges in pharmaceutical sciences. The journal offers various access options to ensure wide dissemination of research findings, making it an essential resource for those dedicated to enhancing public health through pharmaceutical advancements.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, published by Springer/Plenum Publishers, stands as a vital resource in the field of pharmacology. With an ISSN of 1567-567X and an E-ISSN of 1573-8744, this journal is well-regarded within the academic community, as reflected in its Q2 ranking in the 2023 Scopus category for Pharmacology. Spanning years from 1996 to 2024, it serves as a comprehensive platform for cutting-edge research on the interactions of drugs within the body, their effects, and the underlying pharmacological mechanisms. The journal provides a critical avenue for dissemination of significant research findings, with a focus on enhancing understanding in pharmacokinetics, pharmacodynamics, and their implications in therapeutic practices. Targeting an audience of researchers, professionals, and students, the journal emphasizes high-quality manuscripts that contribute to the advancement of knowledge in pharmacology. Although currently not an open access journal, it maintains a strong commitment to promoting scientific communication and collaboration.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, published by WILEY, is a premier journal that serves as a vital resource for researchers, professionals, and students in the fields of pharmacology and physiology. With ISSN 0305-1870 and E-ISSN 1440-1681, this journal has established itself as a significant contributor to scientific dialogue since its inception in 1974. Currently spanning until 2024, it consistently publishes cutting-edge research addressing both experimental and clinical advancements in pharmacology and physiology. Recognized for its quality, it holds a Q2 ranking in the 2023 Pharmacology category and notable Q3 rankings in both Physiology and Medical Physiology. The journal's coverage of topical issues not only ensures a robust platform for innovative findings but also fosters collaborations across disciplines. Although not an Open Access journal, its curated content is invaluable for advancing knowledge, as evidenced by its solid Scopus rankings, which place it within the top percentiles of its field. Engaging with this journal means staying at the forefront of research that shapes clinical practices and experimental methodologies.

Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

Tropical Journal of Pharmaceutical Research is an esteemed open-access platform dedicated to advancing the field of pharmaceutical sciences, published by the Pharmacotherapy Group in Nigeria. With an ISSN of 1596-5996 and open access established since 2002, this journal serves as a critical resource for researchers, professionals, and students seeking to disseminate and access high-quality research in both pharmaceutical science and pharmacology. Despite its ranking in the third quartile (Q3) for Pharmaceutical Science and the fourth quartile (Q4) in Pharmacology as of 2023, the journal continues to stand out with its commitment to fostering significant dialogue and innovation in the scientific community. Anchored at the University of Benin, Faculty of Pharmacy, the journal invites contributions that explore novel pharmaceutical research, clinical applications, and drug development, playing a vital role in addressing health challenges that are particularly relevant to tropical regions. Researchers can look forward to publishing their findings in a journal that not only promotes the sharing of knowledge but also enhances the scientific discourse within a rapidly evolving field.

Drug Metabolism Reviews is a premier journal dedicated to the dissemination of scientific research and reviews in the field of pharmacology, toxicology, and pharmaceutics, published by Taylor & Francis Ltd. With its inception dating back to 1972, this journal has consistently provided an authoritative platform for scholars and professionals from diverse disciplines to explore the intricate mechanisms of drug metabolism and their implications for therapeutic applications. The journal enjoys commendable rankings, placing in the Q2 quartile for Pharmacology (medical) and the Q1 quartile in the miscellaneous subfield, signaling its significant impact within the community. Notably, it is recognized within the top 96th percentile in General Pharmacology, Toxicology and Pharmaceutics, affirming its esteemed position among academic publications. Although it operates under a subscription model, Drug Metabolism Reviews remains an essential resource for researchers, professionals, and students seeking to deepen their understanding of drug interactions, safety, and efficacy. The insights shared within its pages contribute vital knowledge to the global discourse on drug development and personalized medicine.

Drug Metabolism and Pharmacokinetics is a premier academic journal committed to advancing the understanding of drug metabolism processes and pharmacokinetic principles critical to the development of therapeutics. Published by the Japanese Society for the Study of Xenobiotics, this journal has established itself as a vital resource within Pharmaceutical Science and Pharmacology, achieving a respectable Q2 ranking in the latest 2023 metrics. Spanning from 2002 to 2024, the journal publishes original research articles, reviews, and insights that address contemporary issues in xenobiotic metabolism and pharmacologic practices. With its ISSN of 1347-4367 and E-ISSN of 1880-0920, Drug Metabolism and Pharmacokinetics is indexed in leading databases, enhancing its visibility and accessibility for researchers, professionals, and students alike. By fostering a rigorous scientific dialogue, the journal plays an essential role in shaping the future of pharmacology and pharmaceutical sciences.